ALLMedicine™ Chronic Urticaria Center
Research & Reviews 537 results
European Journal of Dermatology : EJD; Melé-Ninot G, Serra-Baldrich E et. al.
Dec 6th, 2022 - The guidelines for the treatment of chronic spontaneous urticaria (CSU) recommend adding omalizumab to the treatment of patients with uncontrolled disease despite four-fold doses of second-generation antihistamines (AH). On the contrary, some stud...
Immunology Qian XJ, Hu XT et. al.
Nov 26th, 2022 - The present study aims to evaluate the efficacy of an anti-immunoglobulin E monoclonal antibody (omalizumab) in the treatment of allergic asthma (AS). A total of 34 patients with moderate-to-severe bronchial asthma admitted to the Respiratory Depa...
Immunology and Allergy Clinics of North America; Pope EM, Laageide L et. al.
Nov 22nd, 2022 - The safe management of allergic skin disorders during pregnancy is essential to maternal and fetal health. Poorly controlled allergic skin disease affects the health of mother and child. This article reviews the disease course and treatment of ato...
Immunology and Allergy Clinics of North America; L Ramos C, Namazy J
Nov 22nd, 2022 - Asthma, allergic rhinitis, chronic urticaria, and atopic dermatitis are common diseases that affect hundreds of thousands of pregnant women each year. The authors discuss the use of biologics in women who are pregnant or lactating, indications, av...
International Immunopharmacology; Ding Y, Dang B et. al.
Nov 21st, 2022 - Chronic urticaria (CU) is a common skin disease that affects about 1% of the world's population of all ages and seriously affects patients' quality of life. Therefore, further safe and effective treatments are urgently needed. Therefore, artemisin...
Drugs 265 results see all →
Clinicaltrials.gov 65 results
Sep 1st, 2022 - Urticaria is a chronic allergic inflammatory disorder. Genetic and environmental factors, such as exposure to allergens and microbes, have a detrimental role in the development of chronic urticaria. Vitamin D also has an important role in urticari...
Aug 26th, 2022 - Chronic urticaria is a condition that impairs the patient's quality of life, interferes with routine daily activities, and is often associated with anxiety. It constitutes a significant burden associated with psychiatric comorbidities such as Fund...
Aug 25th, 2022 - Previous studies reported infraclinical modifications of the homeostasis in chronic urticaria, recurrent idiopathic angioedema and hereditary angioedema. This study aim to compare groups with isolated wheals, isolated angioedema, combination of bo...
Jul 28th, 2022 - There are 58 patients out of 68 participants (10 are Healthy Volunteers)
Jul 19th, 2022 - Chronic urticaria (CU) is an inflammatory skin disease that is defined by the presence of urticaria (hives), on most days of the week, for a period of six weeks or longer. About 40 percent of patients with CU have accompanying episodes of angioede...
News 81 results
Nov 21st, 2022 - Patients suffering from chronic urticaria can easily find bogus causes and treatments online, and providers need to refute the falsehoods with facts, a research letter suggests. "Chronic urticaria can have a major psychological impact, leaving pat...
Oct 12th, 2022 - Most patients with chronic urticaria (CU) used treatment during pregnancy, especially with second-generation antihistamines, which appear to be safe regardless of the trimester. In addition, the rates of preterm births and medical problems of newb...
Oct 11th, 2022 - Most patients with chronic urticaria (CU) used treatment during pregnancy, especially with second-generation antihistamines, which appear to be safe regardless of the trimester. In addition, the rates of preterm births and medical problems of newb.
Sep 15th, 2022 - MILAN – The therapeutic value of inhibiting the activity of IgE in patients with chronic spontaneous urticaria (CSU) was reinforced by two large phase 3 trials with ligelizumab, a drug characterized as a new generation anti-IgE monoclonal antibody...
Sep 14th, 2022 - MILAN – The therapeutic value of inhibiting the activity of IgE in patients with chronic spontaneous urticaria (CSU) was reinforced by two large phase 3 trials with ligelizumab, a drug characterized as a new generation anti-IgE monoclonal antibody.